The compound is a Tyrosin Kinase Inhibitor (type 1). Can also reduce ROS (in HUVEC, TNF-a induced). I need to know which factors are required to be considered/proved in vitro and in vivo to show that the compound is a potential one against atherosclerosis.
Rohit Gundamaraju
ROS is directly associated with arthrosclerosis. If your compound is able to attenuate ROS, I believe you can target and portray ROS pathways. You can approach via anti-oxidant mechanisms for example: Renin induced hypertension and testing your compound. Screening of mitochondrial damage by ROS induction and testing your compound would also be an excellent approach.
1 votes
0 thanks
More Khan Md Taufiqul Arif's questions See All
Similar questions and discussions